A Product Theater for Zepbound® (tirzepatide) Injection Including an Affordability Solution for Taltz® (ixekizumab) Patients

Innovation Theater B, Marriott Marquis Chicago | Developed and offered by Eli Lilly and Company

Program Description

Join a presentation from one of your peers on the efficacy, safety, dosing, and administration of once-weekly Zepbound®. Learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to ask questions at the conclusion of the program.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Please see Full Prescribing Information including Boxed Warning and Medication Guide at the product theater or on https://zepbound.lilly.com.

Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

*This not an official program of the American College of Rheumatology

Speakers

Presenter: Philip J Mease, MD
Swedish Medical Center
Director of Rheumatology Research
Seattle, Washington

Providence-St Joseph Health
Director of Rheumatology Research
Seattle, Washington

Presenter: Samy Metyas, MD
Covina Arthritis Institute
Rheumatologist
Covina, California

University of Southern California
Clinical Associate Professor of Rheumatology
Los Angeles, California